All articles by Sarah Houlton – Page 7
-
News
Abbott splits to set pharma portfolio free
US drug maker divides the firm into two parts as part of a rebalancing strategy
-
News
Dimerised drug leads two pronged attack on HIV
HIV drug dimer can both cross into the brain and inhibit protein pump that expels it
-
Feature
Stemming the tide
Are drug-immune cancer stem cells the root of recurring tumours? And if they are, can we treat them? Sarah Houlton joins in the hunt
-
Feature
Graphene by the kilo
Durham Graphene Science founder Karl Coleman is forging ahead in production of single-layer carbon. Sarah Houlton talks to the 2011 Chemistry World entrepreneur of the year
-
Careers
Who's who: Studying fragrances and flavours
Sarah Houlton tries to entice us into a career in the flavourings and fragrances industry
-
News
Targeting DNA packaging to treat leukaemia
A drug that can attack leukaemia by interfering with DNA organisation is set to start clinical trials soon
-
Careers
The insider: Venturing into business support
Many chemists are ideally suited to careers in venture capital, discovers Sarah Houlton
-
Careers
Profile: Polymer chemist delivers the goods
A career in drug delivery finds polymer chemist Jeff Hrkach working with chemists, biologists, engineers and, ultimately, investors, writes Sarah Houlton
-
Careers
Managing change: A helping hand
Sarah Houlton finds out who would benefit from a career coach. Most of us, apparently...
-
News
US approves cancer drugs twice as fast as Europe
The US approves cancer drugs faster than Europe but future collaboration is likely to iron out differences
-
News
Asbestos linked to ovarian cancer
A meta-analysis of 18 studies has confirmed that asbestos can cause ovarian cancer
-
News
Mosquitoes fooled by compounds that target CO2 sensors
New chemicals can fight mosquito-borne diseases by interfering with the insects' carbon dioxide receptors
-
Careers
Profile: Chemists on a contract
Emma Blaney joins a growing number of chemists leaving big pharma for careers in contract research organisations (CROs), reports Sarah Houlton
-
News
Bacteria could turn coffee waste into drugs
Caffeine-munching bacteria could turn coffee waste into drugs or a feedstock for biofuels
-
News
Cost-cutting will stifle UK innovation
A report claims that the government's penny-pinching attitude to publicly funded services will damage the country's innovative edge
-
News
Takeda expands into Europe with Nycomed deal
Takeda has swallowed up Nycomed in a €10 billion buyout that will give it access to European markets
-
News
Ecstasy substitute poses major health risks
The designer drug benzylpiperazine may damage the kidneys and liver, researchers have discovered
-
News
Benlysta breaks 50 year Lupus drug drought
Antibody becomes the first drug approved for the autoimmune disease since 1955
-
News
Real-world treatment for dye-contaminated effluents
An iron-based catalyst for cleaning industrial wastewater
-
Careers
Company Profile: Chemical ensemble
From Cambridge, UK, to Cambridge, Massachusetts, Sarah Houlton looks at the rewards on offer to chemists in the biotech sector